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Included in this issue of the Annals of Surgical Oncol-
ogy is a comprehensive analysis of risk factors and
outcomes in patients who underwent resection of thoracic
and abdominal malignancies.1 The dataset that the authors
chose to analyze is the deidentified Participant Use Data
File (PUF) of the American College of Surgeons National
Surgical Quality Improvement Program (ACS-NSQIP). As
the authors comment in their manuscript, this is a validated
dataset compiled by trained nurse reviewers at more than
200 U.S. hospitals.2
There are three main strengths of this dataset. First, each
of the multiple preoperative risk factors, intraoperative risk
factors, and postoperative complications (termed ‘‘occur-
rences’’ in the ACS-NSQIP) are strictly defined, allowing
consistency across institutions and personnel. Second,
nurse reviewers complete a 30-day postoperative data
collection, accounting for occurrences and deaths that
occurred during the early postdischarge period. Third, the
timeliness and size of the dataset (including 635,265 cases
from 2005 to 2008) adds power to detailed outcomes
analyses.
The manuscript leverages each of these factors to com-
ment on the ability to prognosticate complications after a
mixed group of complex surgical oncology operations from
pneumonectomy to pelvic exenteration. In their multivariate
analyses, they identify multiple important risk factors for
postoperative outcomes, such as older age, performance
status, ASA score, serum albumin, and intraoperative
transfusion. These findings validate multiple previous ACS-
NSQIP risk models, indicating that the core set of risk factors
for poor outcome in all general surgery patients also apply to
patients who require complex cancer operations.
The authors then rate the ability of their cancer proce-
dure-specific multivariate models to account for all of the
adverse outcomes that occurred. Using the c-index statistic
as their metric, the authors find that, despite the power of
the large number of cases analyzed, their models were only
able to predict a portion of the complications and deaths
that occurred. The important question then becomes ‘‘Why
can’t we use the ACS-NSQIP database (arguably the
largest, most complete, objective, and accurate compilation
of surgical risk factors and outcomes) to identify the subset
of risk factors that perfectly correlates with postoperative
adverse outcome?’’
The authors offer several explanations for the discrep-
ancy between the quality of the dataset and the
imperfection of its predictive models. First, they argue that
missing data confounded the predictive power of the
models, citing the finding that 13% of the 398 patients
recorded as 30-day postoperative mortalities had no
recorded ‘‘major complications’’ (the subset of occurrences
defined by the authors as ‘‘major complications’’ is detailed
in the Methods section). Although we cannot comment on
the exact subset of patients that the authors chose to ana-
lyze, by using a definition of major complications similar
to theirs (which we have previously published3) an audit
finds that 3,247 of the 635,265 cases (0.51%) in the PUF
are recorded as 30-day mortalities without major compli-
cation. In 1,024 of these cases (31.5%) with apparent
missing data, the death occurred after hospital discharge. In
this scenario, a nurse reviewer may have a patient with no
inpatient postoperative complications, who then has a
sudden death event after discharge. Without medical input
concerning the exact cause of death, this case would be
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coded as a 30-day mortality without major complication.
Admittedly a potential weakness of the database, crucial
missing data appears to be a rare event that should not
adversely impact risk modeling.
The second major reason that the authors use to explain
the discrepancy between data quality and predictive ability
is lack of definitions and recording of operation-specific
outcomes. This point is well recognized and well taken.
Given the current ACS-NSQIP occurrence definitions,
complications, such as bile leak after liver resection and
pancreatic fistula after pancreaticoduodenectomy, may be
captured in such categories as deep space surgical site
infection, but this is not certain. During the past 2 years,
multiple ACS-NSQIP–engaged cancer surgeons have
focused on this issue. One immediate remedy is that each
ACS-NSQIP institution has a set of open data fields
available to collect such specific data. As well, collabora-
tion between ACS-NSQIP and subspecialty surgical
societies is active to create consensus on definitions of such
occurrences, facilitating uniform entry into the national
data collection algorithm.4
To that end, the Society of Surgical Oncology mem-
bership has an opportunity to propose cancer-specific risk
factors that likely contribute to adverse postoperative out-
comes. For example, the ACS-NSQIP definition of
‘‘preoperative chemotherapy’’ is neoadjuvant treatment
within 1 month of surgical resection. Based on this defi-
nition, a patient who received 6 cycles of FOLFOX with
Avastin for colorectal liver metastases, whose therapy was
discontinued 6 weeks before surgery to reduce the risk
(perceived or real) of complications, would not be coded as
having preoperative chemotherapy in the current ACS-
NSQIP lexicon. Given that this patient’s risk for preoper-
ative anemia, and therefore perioperative transfusion
requirements, among several other adverse outcomes, is
likely higher than a chemotherapy-naı¨ve patient,5 a more
complete definition of the term ‘‘preoperative chemother-
apy’’ may empower future ACS-NSQIP–derived risk
models to better predict outcomes in cancer patients.
Pathologic stage of cancer is another example of a cancer
patient-specific variable that may impact perioperative
outcomes but is not currently recorded in the ACS-NSQIP.
One final point to consider is that when we speak about
‘‘major cancer surgery,’’ we immediately encounter two
features that automatically add variability to any prognostic
model. As the complexity of an operation increases, the
prognostic weight of any one or any combination of pre-
operative risk factors is diminished. Likewise, cancer in
and of itself, likely through effects on the immune system,
increases the rate of apparently random events that occur
during the perioperative period. These factors conspire to
put a ceiling on the maximal c-index that can be derived
from any risk model. This does not mean that we should
stop trying to identify perioperative risk factors for adverse
postoperative outcomes in cancer surgery; instead this
presents an opportunity to refine surgical outcomes dat-
abases, such as the ACS-NSQIP PUF. This would allow us
to better understand practice patterns and systems of care
that are rigid enough to reliably manage the known risk
factors and flexible enough to respond to the random
unpredictable events.6 This hybrid ability is where the best
final outcomes in major cancer surgery will be found.
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